ASP2905

ASP2905 is an investigational small molecule inhibitor of the KCNH3 (also known as BEC1 or Kv12.2) voltage-gated potassium channel, originally developed by Astellas Pharma. KCNH3 is a member of the ether-à-go-go family of potassium channels and is highly expressed in the forebrain, particularly in areas associated with cognitive function. By selectively inhibiting these channels, ASP2905 aims to enhance cognitive performance and has shown antipsychotic-like activity in preclinical models. It has been investigated for the treatment of cognitive deficits in Alzheimer's disease, schizophrenia, and attention deficit hyperactivity disorder (ADHD). The compound was licensed to EMERpharma under the code EM902 for continued development in psychiatric indications.

Other names

N-(4-fluorophenyl)-N'-phenyl-N''-(pyrimidin-2-ylmethyl)-1,3,5-triazine-2,4,6-triamine